Document is current
Any future updates will be listed below
-
Authors
Nakajima, Akihiro
Yanagimura, Fumihiro
Saji, Etsuji
Shimizu, Hiroshi
Toyoshima, Yasuko
Yanagawa, Kaori
Arakawa, Musashi
Hokari, Mariko
Yokoseki, Akiko
Wakasugi, Takahiro
Okamoto, Kouichirou
Takebayashi, Hirohide
Fujii, Chihiro
Itoh, Kyoko
Takei, Yo-ichi
Ohara, Shinji
Yamada, Mitsunori
Takahashi, Hitoshi
Nishizawa, Masatoyo
Igarashi, Hironaka
Kakita, Akiyoshi
Onodera, Osamu
Kawachi, Izumi https://orcid.org/0000-0002-7140-8500
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP20K07899)
Japan Society for the Promotion of Science (JP23K06923)
Japan Society for the Promotion of Science (JP21K07412)
MHLW Research Program on Rare and Intractable Diseases (JPMH 20FC1030)
MHLW Research Program on Rare and Intractable Diseases (JPMH 23FC1009)
- License Information
-
More Information
Article History
Received: 13 February 2024
Revised: 21 March 2024
Accepted: 25 March 2024
First Online: 24 April 2024
Declarations
:
: AN, FY, ES, HS, YT, KY, MA, MH, AY, TW, KO, H.Takebayashi, CF, KI, YT, SO, MY, H. Takahashi, MN, HI, AK, and OO have no competing interests to disclose. IK reports receiving funding for research, travel, and/or speaker’s honoraria from Chugai Pharmaceuticals, Novartis Pharma, Biogen, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Teijin Pharma, Argenx, and Daiichi-Sankyo and is a scientific advisory board member for Mitsubishi Tanabe Pharma and Chugai Pharmaceuticals.
